ICON PLC
ICLRNext catalyst
BXQ-350
Metastatic Colorectal Carcinoma
Get an email about ICLR's next catalysts
Track ICON (ICLR) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 3 more upcoming events in our data (Phase 2 readout, Phase 3 readout).See the timeline
4 upcoming, 1 past
BXQ-350 Phase 2 Est. Readout (ASIST)
Estimated primary completion for BXQ-350 trial (NCT05322590) in Metastatic Colorectal Carcinoma. Topline data typically follows completion by weeks to months.
SourceHT-001 Topical Phase 2 Est. Readout (CLEER)
Estimated primary completion for HT-001 Topical trial (NCT05639933) in Acneiform Eruption Due to Chemical. Topline data typically follows completion by weeks to months.
SourceSP-420 Phase 2 Est. Readout
Estimated primary completion for SP-420 trial (NCT05693909) in Beta Thalassemia Major Anemia. Topline data typically follows completion by weeks to months.
SourcePRX-102 Phase 3 Est. Readout (RISE)
Estimated primary completion for PRX-102 trial (NCT05710692) in Fabry Disease. Topline data typically follows completion by weeks to months.
SourceMarket Overview
Stock performance and key metrics
Icon plc (stylized as "ICON") is an Irish-headquartered multinational clinical research organisation (CRO). Icon conducts clinical trials on behalf of pharmaceutical and biotechnology companies and provides services related to drug development and guiding clinical trial progress.
WebsiteBT524 (Part I)
Congenital Afibrinogenemia
BT524
Bleeding Disorder
Estetrol
Vasomotor Symptoms
EcN-Suspension
Infections
Estetrol oral tablet
Vasomotor Symptoms
IgPro20 (low dose)
Chronic Inflammatory Demyelinating Polyneuropathy
IgPro10
Chronic Inflammatory Demyelinating Polyneuropathy
CureXcell®
Lower Extremity Chronic Ulcers in Diabetics
CC-5013
Melanoma
IgPro20 (high dose)
Chronic Inflammatory Demyelinating Polyneuropathy
Apabetalone
Diabetes Mellitus, Type 2
Clascoterone
Alopecia, Androgenetic
padeliporfin VTP
Transitional Cell Cancer of Renal Pelvis and Ureter
Necitumumab
Non Small Cell Lung Cancer
IBI-10090
Inflammation
PRX-102
Fabry Disease
BT524 (Part II)
Congenital Afibrinogenemia
FCM (Ferric carboxymaltose) low ferritin target
Iron Deficiency Anaemia
VAS203
Traumatic Brain Injury
Belimumab
Connective Tissue Diseases
PRX-102 every two weeks
Fabry Disease
15 MBq/kg Betalutin
Non-Hodgkin Lymphoma
lilotomab
Non-Hodgkin Lymphoma
H5N8 antigen plus MF59
Influenza
AV7909 Half
Anthrax
20 MBq/kg Betalutin
Non-Hodgkin Lymphoma
IX-01
Premature Ejaculation
H5N1 antigen plus MF59
Influenza
Vosoritide
Hypochondroplasia
Methoxsalen +ECP
Crohn's Disease
AV7909 Full
Anthrax
SP-420
Beta Thalassemia Major Anemia
tideglusib
Alzheimer's Disease
10 MBq/kg Betalutin
Non-Hodgkin Lymphoma
BXQ-350
Metastatic Colorectal Carcinoma
Antroquinonol
Non-small Cell Lung Cancer Stage IV
IBI-20089/Lucentis
Age-Related Macular Degeneration
Avotermin
Varicose Veins
HT-001 Topical
Acneiform Eruption Due to Chemical
Bendavia (MTP-131)
Reperfusion Injury
Xanamem™
Dementia, Alzheimer Type
TU-100
Irritable Bowel Syndrome in Females
FP-101
Vasomotor Symptoms
H5N8 antigen plus full dose AS03A
Influenza
12.5 mBq/kg Betalutin
Non-Hodgkin Lymphoma
H5N1 antigen plus full dose AS03A
Influenza
H5N8 antigen plus half dose AS03A
Influenza
EDP-305 Dose 2
Non-Alcoholic Steatohepatitis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
BT524 (Part I) | Phase 3 | Congenital Afibrinogenemia | - | - |
BT524 | Phase 3 | Bleeding Disorder | - | - |
Estetrol | Phase 3 | Vasomotor Symptoms | - | - |
EcN-Suspension | Phase 3 | Infections | - | - |
Estetrol oral tablet | Phase 3 | Vasomotor Symptoms | - | - |
IgPro20 (low dose) | Phase 3 | Chronic Inflammatory Demyelinating Polyneuropathy | - | - |
IgPro10 | Phase 3 | Chronic Inflammatory Demyelinating Polyneuropathy | - | - |
CureXcell® | Phase 3 | Lower Extremity Chronic Ulcers in Diabetics | - | - |
CC-5013 | Phase 3 | Melanoma | - | - |
IgPro20 (high dose) | Phase 3 | Chronic Inflammatory Demyelinating Polyneuropathy | - | - |
Apabetalone | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
Clascoterone | Phase 3 | Alopecia, Androgenetic | - | - |
padeliporfin VTP | Phase 3 | Transitional Cell Cancer of Renal Pelvis and Ureter | - | - |
Necitumumab | Phase 3 | Non Small Cell Lung Cancer | - | - |
IBI-10090 | Phase 3 | Inflammation | - | - |
PRX-102 | Phase 3 | Fabry Disease | - | - |
BT524 (Part II) | Phase 3 | Congenital Afibrinogenemia | - | - |
FCM (Ferric carboxymaltose) low ferritin target | Phase 3 | Iron Deficiency Anaemia | - | - |
VAS203 | Phase 3 | Traumatic Brain Injury | - | - |
Belimumab | Phase 3 | Connective Tissue Diseases | - | - |
PRX-102 every two weeks | Phase 3 | Fabry Disease | - | - |
15 MBq/kg Betalutin | Phase 2 | Non-Hodgkin Lymphoma | - | - |
lilotomab | Phase 2 | Non-Hodgkin Lymphoma | - | - |
H5N8 antigen plus MF59 | Phase 2 | Influenza | - | - |
AV7909 Half | Phase 2 | Anthrax | - | - |
20 MBq/kg Betalutin | Phase 2 | Non-Hodgkin Lymphoma | - | - |
IX-01 | Phase 2 | Premature Ejaculation | - | - |
H5N1 antigen plus MF59 | Phase 2 | Influenza | - | - |
Vosoritide | Phase 2 | Hypochondroplasia | - | - |
Methoxsalen +ECP | Phase 2 | Crohn's Disease | - | - |
AV7909 Full | Phase 2 | Anthrax | - | - |
SP-420 | Phase 2 | Beta Thalassemia Major Anemia | - | - |
tideglusib | Phase 2 | Alzheimer's Disease | - | - |
10 MBq/kg Betalutin | Phase 2 | Non-Hodgkin Lymphoma | - | - |
BXQ-350 | Phase 2 | Metastatic Colorectal Carcinoma | - | - |
Antroquinonol | Phase 2 | Non-small Cell Lung Cancer Stage IV | - | - |
IBI-20089/Lucentis | Phase 2 | Age-Related Macular Degeneration | - | - |
Avotermin | Phase 2 | Varicose Veins | - | - |
HT-001 Topical | Phase 2 | Acneiform Eruption Due to Chemical | - | - |
Bendavia (MTP-131) | Phase 2 | Reperfusion Injury | - | - |
Xanamem™ | Phase 2 | Dementia, Alzheimer Type | - | - |
TU-100 | Phase 2 | Irritable Bowel Syndrome in Females | - | - |
FP-101 | Phase 2 | Vasomotor Symptoms | - | - |
H5N8 antigen plus full dose AS03A | Phase 2 | Influenza | - | - |
12.5 mBq/kg Betalutin | Phase 2 | Non-Hodgkin Lymphoma | - | - |
H5N1 antigen plus full dose AS03A | Phase 2 | Influenza | - | - |
H5N8 antigen plus half dose AS03A | Phase 2 | Influenza | - | - |
EDP-305 Dose 2 | Phase 2 | Non-Alcoholic Steatohepatitis | - | - |
Frequently asked questions
What is in ICON PLC's drug pipeline?→
CatalystAlert tracks 48 drug candidates in ICON PLC's (ICLR) pipeline across Phase 3, Phase 2. Its lead program is PRX-102 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is ICON PLC's next FDA catalyst?→
ICON PLC's (ICLR) next tracked catalyst is a Phase 2 readout expected November 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ICLR biotech catalysts?→
Add ICLR to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow ICON PLC's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.